Skip to content

DEVELOPMENT pipeline

33 Clinical projects
16 Phase 1
6 Phase 2
6 Phase 3
5 Filling

Oncology

SOLID TUMORS

Compound / MOA
Project
Therapeutic area
Phase
FTD/TPI combo bevacizumab
S95005
Solid tumors (new indication)
DPC
1
2
3
Futuximab / modotuximab
combo FTD/TPI
S95026
Solid tumors (new indication)
DPC
1
2
3
Vorasidenib
S95032
Low grade Glioma with IDH 1/2 mutation
DPC
1
2
3
Ivosidenib
S95031
Solid tumors (new indication)
DPC
1
2
3
Anti-MET
S95027
Non small Cell Lung Cancer
DPC
1
2
3
Vorasidenib + pembrolizumab
S95032
Grade 2-3 glioma with IDH1/2 mutation
DPC
1/2
3
Ivosidenib combo
S95031
Solid tumors (new indication)
DPC
1/2
3
Anti-TIM3 combo
S95018
Solid tumors
DPC
1/2
3
Anti-CD73
S95024
Solid tumors
DPC
1/2
3
Anti-PD-L1/4-1BB
S95012
Solid tumors
DPC
1/2
3
Anti-NKG2A
S95029
Solid tumors
DPC
1/2
3
Inhibiteur de MAT2A
S95035
Solid tumors
DPC
1
2
3
Anti-FLT3
S95040
Solid tumors
DPC
1
2
3

HEMATOLOGICAL MALIGNANCIES

Compound / MOA
Project
Therapeutic area
Phase
Ivosidenib + 7+3 (chimio)
S95031
Hematological malignancies (new indication)
DPC
1
2
3
UCART 19
S68587/S95023
Hematological malignancies
DPC
1
2
3
Calaspargase pegol
S95015
Hematological malignancies (new indication)
DPC
1
2
3
Pegaspargase
S95014
Hematological malignancies (new formulation)
DPC
1
2
3
Ivosidenib
S95031
Hematological malignancies (new indication)
DPC
1/2
3
BCL-2 inhibitor + Mcl1 inhibitor (S64315)
S65487
Acute Myeloid Leukemia
DPC
1/2
3
BCL-2 inhibitor + azacitidine
S65487
1st line Acute Myeloid Leukemia (AML)
DPC
1/2
3
Mcl1 inhibitor + azacitidine
S64315
Relapsed/Refractory Acute Myeloid Leukemia (AML)
DPC
1/2
3

Neuroscience

Compound / MOA
Project
Therapeutic area
Phase
LRRK2 inhibitor
S221237
Parkinson’s Disease
DPC
1
2
3

Immuno-inflammation

Compound / MOA
Project
Therapeutic area
Phase
Anti-IL7R
S95011
Sjögren syndrome
DPC
1
2
3
Anti-IL7R
S95011
Ulcerative colitis
DPC
1
2
3

PCD= Preclinical development phase, 1 = Phase 1, 2 = Phase 2, 3 = Phase 3; FTD/TPI: trifluridine/ tipiracil; EGFR: epidermal growth factor receptor; IDH: Isocitrate dehydrogenase; AYA: Adolescents and Young Adults; MOA: Mode of Action